Decode and design T cell induction by a complex gut microbial community
复杂肠道微生物群落解码和设计 T 细胞诱导
基本信息
- 批准号:10572613
- 负责人:
- 金额:$ 13.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-11 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Advisory CommitteesAnti-Inflammatory AgentsAntigensAutoimmune DiseasesAwardB-LymphocytesBacteriaBacterial AntigensBiologicalCD4 Positive T LymphocytesCell CommunicationCell LineCell physiologyCellsCellular biologyCoculture TechniquesColitisCommunicable DiseasesCommunitiesComplementComplexDiseaseDropoutDropsEcosystemEpitopesEscherichia coliFecesGene ClusterGerm-FreeGoalsHumanHuman MicrobiomeHybridomasImmuneImmune responseImmune systemImmunologicsImmunologyIndividualInflammatoryInflammatory Bowel DiseasesInterleukin-10KnowledgeLibrariesLogicMHC antigenMalignant NeoplasmsMentorsMentorshipMetabolic DiseasesMetagenomicsMethodsMicrobeMicrobiologyModelingMolecularMolecular BiologyMusPaperPatternPeptide LibraryPhenotypePhysiologicalRegulatory T-LymphocyteReportingResearchResolutionRoleShotgunsSignal TransductionSiteStimulusT cell responseT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsTCR ActivationTaxonomyTechnologyTestingTherapeuticTherapeutic EffectTimeTrainingVariantWorkadaptive immune responseantigen-specific T cellsbacterial communitybacterial geneticscancer therapydesignfecal transplantationgenetic signaturegut microbiomegut microbiotahost-microbe interactionsimmune functionimmunoreactionimmunoregulationimprovedin vivoinsightmedical specialtiesmembermicrobialmicrobial communitymicrobiomemicrobiome componentsmicrobiotamouse modelneglectnew technologynovel therapeutic interventionnovel therapeuticspredictive toolsprogramsrational designresponsescreeningsingle cell technologythree dimensional structuretool
项目摘要
Project Summary/Abstract
Immune modulation holds tremendous promise for the treatment of cancer, autoimmune disease, metabolic
disease, and infectious disease. New ways to generate antigen-specific T and B cells inexpensively and with
minimal reactogenicity are badly needed. Certain bacterial strains from the gut microbiome elicit a potent,
specific adaptive immune response. The underlying mechanisms could guide new therapeutic strategies in
which bacteria-specific immune responses are rationally altered or re-directed. The gut is the site of a wide
variety of microbe-microbe and microbe-host interactions. However previous papers have characterized
microbial strains of the microbiome under artificial conditions of mono-colonization. This approach can identify
strains that are capable of modulating immune cells, but it is unknown how a strain functions in the presence of
other members of the complex microbiota. This knowledge gap hinders a logical design of a microbial
therapeutic.
My long-term research objective is to develop new technologies to understand the “physiological” gut
ecosystem at the level of molecular mechanisms so that I can identify immune modulatory bacteria from the
microbiome and build new therapeutics. In this proposal, I will establish a “physiological” gut by colonizing
germ-free mice with a complex defined gut community (104 strains) and profile T cell responses to each strain
individually. In Aim1, I will identify a set of bacteria-reactive TCRs and their stimulatory strain by single cell
technologies, so that I can provide a big picture of the strain-T-cell interactions at the single TCR level. In
Aim2, I will identify and characterize a bacterial antigen common to multiple strains. In Aim3, the result of T cell
profiling will be used to “design” therapeutic bacterial communities in which inflammatory strains will be
dropped out for building a tolerogenic community to treat colitis in an IBD mouse model. The successful
completion of this project will “decode” a strain-by-strain view of immune modulation by the gut microbiome
and provide a molecular basis for “designing” the new therapy that logically modulates immune response to
treat IBD and other devastating systemic disorders.
Support from the K99 and mentors will complement my expertise in immunology with state-of-art
technologies in microbiology and single cell biology. I will accomplish this with training from Dr. Michael
Fischbach (primary mentor, bacterial genetics), Dr. Daniel Mucida (co-mentor, single-cell biology and T cell
biology), Dr. Justin Sonnenburg (advisory committee, metagenomic analysis), and Dr KC Huang, (advisory
committee, a synthetic microbial community). The training and mentorship I receive during my K99/R00 award
will provide a critical stepping stone for me to achieve my academic goal of establishing a vibrant independent
research program that can answer an important question in the gut ecosystem for establishing a new
therapeutic.
项目摘要/摘要
免疫调节为癌症、自身免疫性疾病、代谢疾病的治疗带来了巨大的希望
疾病和传染病。产生抗原特异性T和B细胞的新方法
最小的反应性是迫切需要的。肠道微生物群中的某些细菌菌株能诱导出一种有效的、
特异性适应性免疫反应。潜在的机制可以指导新的治疗策略
哪些细菌特异的免疫反应被合理地改变或重新定向。肠子是一块很宽的地方
微生物-微生物和微生物-宿主相互作用的多样性。然而,之前的论文描述了
微生物菌群在人工条件下的单定植。这种方法可以识别
能够调节免疫细胞的菌株,但目前尚不清楚菌株在存在
复合微生物区系的其他成员。这种知识鸿沟阻碍了微生物的逻辑设计
有治疗作用。
我的长期研究目标是开发新的技术来理解“生理”的肠道
在分子机制水平上的生态系统,使我可以识别免疫调节细菌从
微生物组和建立新的治疗方法。在这项提议中,我将通过殖民建立一种“生理”的内脏
具有复杂定义肠道群落的无菌小鼠(104个菌株)和对每个菌株的T细胞反应谱
单独的。在Aim1中,我将通过单细胞鉴定一组细菌反应性TCR及其刺激菌株
技术,这样我就可以在单个TCR水平上提供菌株-T细胞相互作用的总体图景。在……里面
AIM2,我将鉴定和鉴定一种对多种菌株通用的细菌抗原。在Aim3,T细胞的结果
分析将被用来“设计”治疗细菌群落,在其中炎性菌株将
在IBD小鼠模型中建立耐受性社区来治疗结肠炎而辍学。成功者
该项目的完成将“破译”肠道微生物群对免疫调节的一株一株的观点。
并为“设计”合理调节免疫反应的新疗法提供了分子基础
治疗IBD和其他破坏性的全身性疾病。
来自K99和导师的支持将用最先进的技术补充我在免疫学方面的专业知识
微生物学和单细胞生物学技术。我将通过迈克尔博士的培训来实现这一点
Fischbach(主要导师,细菌遗传学),Daniel Mucida博士(单细胞生物学和T细胞共同导师)
生物学),Justin Sonnenburg博士(咨询委员会,元基因组分析),KC Huang博士,(咨询
委员会,合成微生物群落)。我在K99/R00大奖期间接受的培训和指导
将为我实现我的学术目标--建立一个充满活力的独立的
研究计划,可以回答肠道生态系统中的一个重要问题,以建立一个新的
有治疗作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kazuki Nagashima其他文献
Kazuki Nagashima的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 13.21万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 13.21万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 13.21万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 13.21万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 13.21万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 13.21万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 13.21万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 13.21万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 13.21万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 13.21万 - 项目类别: